FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Dexamethasone | Multiple Myeloma | PHASE2 | WITHDRAWN |
| Foralumab | Secondary Progressive Multiple Sclerosis | PHASE2 | ACTIVE_NOT_RECRUITING |
| Foralumab Nasal | Multiple System Atrophy | PHASE2 | RECRUITING |
| Foralumab TZLS-401 100 µg | Non-Active Secondary Progressive Multiple Sclerosi | PHASE2 | RECRUITING |
| Foralumab TZLS-401 50 µg | Dementia | PHASE2 | RECRUITING |
| Lenalidomide | Multiple Myeloma | PHASE2 | WITHDRAWN |
| Milciclib Dose: 150 mg/day Mode of admin | NSCLC | PHASE2 | UNKNOWN |
| Milciclib maleate | Malignant Thymoma | PHASE2 | TERMINATED |
| Omeprazole 20mg | NASH - Nonalcoholic Steatohepatitis | PHASE2 | WITHDRAWN |
| Vorinostat | Multiple Myeloma | PHASE2 | WITHDRAWN |
TLSA holds $4M in cash and burns about $3.2M/quarter from operations, giving an estimated runway of 3.7 months.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for TLSA free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-08-07 | CERRONE GABRIELE M |
Purchase | $49.7M |
| 2026-08-07 | CERRONE GABRIELE M |
Purchase | $44.4M |
| 2026-08-06 | Elrifi Ivor |
Purchase | $4.4M |
| 2026-08-06 | Elrifi Ivor |
Purchase | $4.8M |
| 2026-08-05 | Elrifi Ivor |
Purchase | $4.5M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for TLSA and 2 more tickers of your choice.
Create Free Account →